Search results for "Mama"

showing 10 items of 106 documents

Molecular epidemiology of astrovirus infection in Italian children with gastroenteritis

2004

A 1-year study involving 157 gastroenteritis samples was conducted to investigate the role of human astrovirus, (HAstV) as a cause of gastroenteritis in Italian children aged < 2 years. The overall incidence of HAstV was 3.1%. Most cases occurred between March and May, and four of the five isolates were of the HAstV-1 type, the other being HAstV-3. Analysis of genetic variability showed that the three HAstV-1 isolates collected in 2000 clustered together, but separately from the 1999 isolate. The results indicated that HAstV should be considered as a potential diarrhoeal pathogen in Italian children. © 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

MaleMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/17 - Malattie InfettiveVirusAstrovirusCell LineAstroviruschildrenAstroviridae InfectionsmedicineHumansTypingPhylogenyMolecular EpidemiologyMolecular epidemiologybiologybusiness.industrytypingInfantGeneral MedicineHuman astrovirusbiology.organism_classificationVirologyGastroenteritisMolecular Epidemiology* Astroviridae Infections/*epidemiology Gastroenteritis/*epidemiology Mamastrovirus/*genetics Astroviridae Infections/virologydiarrhoeaDiarrheaInfectious DiseasesItalyChild PreschoolImmunologyastrovirus epidemiologyFemaleepidemiologymedicine.symptombusinessMamastrovirus
researchProduct

Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer.

2017

Biological changes that occur during metastatic progression of breast cancer are still incompletely characterized. In this study, we compared intrinsic molecular subtypes and gene expression in 123 paired primary and metastatic tissues from breast cancer patients. Intrinsic subtype was identified using a PAM50 classifier and χ2 tests determined the differences in variable distribution. The rate of subtype conversion was 0% in basal-like tumors, 23.1% in HER2-enriched (HER2-E) tumors, 30.0% in luminal B tumors, and 55.3% in luminal A tumors. In 40.2% of cases, luminal A tumors converted to luminal B tumors, whereas in 14.3% of cases luminal A and B tumors converted to HER2-E tumors. We ident…

Mama -- Càncer -- Aspectes genètics0301 basic medicineCancer ResearchPathologyReceptor ErbB-2DiseaseTranscriptome0302 clinical medicineGene expressionSurvival outcomes Letrozole Concordance Predictor Disease Impact Brain Cells Women RiskSurvival outcomesDiseaseNeoplasm Metastasisskin and connective tissue diseasesRegulation of gene expressionAged 80 and overBrainCells WomenMiddle AgedPrognosisMetastatic breast cancerNeoplasm ProteinsGene Expression Regulation NeoplasticImpactOncology030220 oncology & carcinogenesisLetrozoleFemaleRiskAdultmedicine.medical_specialtymedicine.drug_classBreast NeoplasmsBiologyArticle03 medical and health sciencesBreast cancerConcordancemedicineBiomarkers TumorHumansGeneAgedEstrogensmedicine.disease030104 developmental biologyEstrogenNeoplasm Recurrence LocalTranscriptomePredictor
researchProduct

Lineage diversification and recombination in type-4 human astroviruses.

2013

Abstract Human astroviruses (HAstVs) are important enteric pathogens and can be classified genetically and antigenically into eight types. During surveillance of HAstVs in Italy, type-4 HAstVs were detected only sporadically and found to cluster into two distinct genetic groups. Upon sequence analysis of the 3′ end of the polymerase gene (ORF1b) and of the full-length ORF2, the 2008 type-4 HAstV strains were characterised as a novel ORF2 genetic lineage, designated as 4c. The 2008 type-4 HAstVs also shared the ORF1b gene with similar HAstV-4c strains detected globally, thus displaying a conserved ORF1b/ORF2 asset. By interrogation of the databases, this novel lineage 4c accounted for 60.8% …

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaLineage (genetic)Sequence analysisMolecular Sequence DataSequence alignmentBiologyMicrobiologyAstrovirusFecesOpen Reading FramesAstrovirus Epidemiology Genotyping Italy Viral gastroenteritisPhylogeneticsAstroviridae InfectionsGenetic variationGeneticsHumansAmino Acid SequenceMolecular BiologyGenotypingGeneEcology Evolution Behavior and SystematicsPhylogenyGeneticsRecombination GeneticBase SequenceSequence Homology Amino AcidSequence Analysis RNAvirus diseasesGenetic Variationbiology.organism_classificationRNA-Dependent RNA PolymeraseGastroenteritisInfectious DiseasesRNA ViralCapsid ProteinsSequence AlignmentMamastrovirusInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases
researchProduct

Surveillance of human astrovirus circulation in Italy 2002-2005: emergence of lineage 2c strains.

2010

AbstractBy screening faecal samples collected over four consecutive years (2002-2005) from hospitalized children with diarrhoea in Palermo, Italy, astroviruses (HAstVs) were detected in 3.95% of the patients. The predominant type circulating was HAstV-1 but, in 2002, only HAstV-2 and -4 were identified. Interestingly, the HAstVs-2 detected appeared to be consistently different in 5′ end of their open reading frame 2 from the previously described subtypes. These novel type 2 strains were included in a new 2c lineage based on the phylogenetic analysis and the presence of nine peculiar substitutions.

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaPathologymedicine.medical_specialtyLineage (genetic)Settore MED/17 - Malattie Infettivesequence analysisSequence analysisMolecular Sequence DataPolymorphism Single NucleotideVirusAstrovirusAstrovirusFecesAstroviridae InfectionsGenotypePrevalenceMedicineHumansTypingChildGenotypingPhylogenyMolecular EpidemiologybiologyPhylogenetic treebusiness.industryGeneral Medicinebiology.organism_classificationVirologyAstrovirus gastroenteritis genotyping Italy sequence analysisInfectious DiseasesgenotypingItalyPopulation SurveillanceRNA ViralbusinessgastroenteritisMamastrovirusClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
researchProduct

Genetic heterogeneity and recombination in human type 2 astroviruses

2012

ABSTRACT Novel lineages of human astrovirus (HAstV) types 2, 2c, and 2d have been identified. Upon sequencing of the 3′ end of the genome, the type 2c and 2d HAstVs were found to be open reading frame 1b (ORF1b)-ORF2 recombinant, with ORF1b being derived from type 3 and type 1 HAstVs, respectively. An ORF2 interlineage recombinant strain, 2c/2b, was also identified.

Microbiology (medical)Settore MED/07 - Microbiologia E Microbiologia Clinicafood.ingredientMolecular Sequence DataBiologyGenomelaw.inventionGenetic HeterogeneityOpen Reading FramesfoodPhylogeneticslawVirologyCluster AnalysisHumansPhylogenyRecombination GeneticGeneticsGenetic heterogeneityStrain (biology)MamastrovirusSequence Analysis DNAOpen reading frameRecombinant DNARNA Viralastrovirus genotyping ItalyRecombinationMamastrovirus
researchProduct

First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

2021

Anàlisi de seqüències d'ADN; Subtipus PAM50; Genètica molecular Análisis de secuencias de ADN; Subtipo PAM50; Genética molecular DNA sequence analyses; PAM50 subtype; Molecular genetic Background: The SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain. Methods: DNA sequencing of 74 cancer-related genes was performed using FFPE tumor samples in three different laboratories with three different gene panels. A multidisciplinary advisory board prospectively recommended potential targeted trea…

OncologyCancer ResearchDNA Alterationmedicine.medical_specialtymolecular targeted therapyAdvanced breast:Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES]Cancer therapy:terapéutica::farmacoterapia::terapia molecular selectiva [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]:Therapeutics::Drug Therapy::Molecular Targeted Therapy [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Breast cancerbreast cancerInternal medicineGene panelmolecular geneticmedicineDNA sequence analysesRC254-282Original ResearchFarmacologia molecular:neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES]:Natural Science Disciplines::Biological Science Disciplines::Biology::Computational Biology::Genomics [DISCIPLINES AND OCCUPATIONS]Molecular screeningbusiness.industryCancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseOncologyMama - Càncer - Tractament:disciplinas de las ciencias naturales::disciplinas de las ciencias biológicas::biología::biología computacional::genómica [DISCIPLINAS Y OCUPACIONES]Mama - Càncer - Aspectes molecularsPAM50 subtypebusiness
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct

Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers

2012

Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. Four single-nucleotide polymorphisms (SNPs), rs10088218 (at 8q24), rs2665390 (at 3q25), rs717852 (at 2q31), and rs9303542 (at 17q21), were genotyped in 12,599 BRCA1 and 7,132 BRCA2 carriers, including 2,678 ovarian cancer cases. Associations were evaluated within a retrospective cohort approach. All four loci were associated with ovarian …

Oncologyendocrine system diseases[SDV]Life Sciences [q-bio]Càncer d'ovariDCN PAC - Perception action and controlCohort StudiesBreast cancer0302 clinical medicinebrca1brca2Odds RatioGenetics (clinical)ComputingMilieux_MISCELLANEOUSOvarian NeoplasmsGenetics0303 health scienceseducation.field_of_studyBRCA1 ProteinHazard ratioMiddle Aged3. Good healthovarian cancer030220 oncology & carcinogenesisFemaleAdultHeterozygotemedicine.medical_specialtyHereditary cancer and cancer-related syndromes Genetics and epigenetic pathways of disease [ONCOL 1]PopulationSingle-nucleotide polymorphismBiologyOvarian Neoplasms - geneticsPolymorphism Single NucleotideArticleCàncer de mama03 medical and health sciencesBreast cancerGermline mutationSDG 3 - Good Health and Well-beingTranslational research [ONCOL 3]Ovarian cancerInternal medicineGeneticsmedicineHumansGenetic Predisposition to Diseaseddc:610Genetics and epigenetic pathways of disease Translational research [NCMLS 6]educationRetrospective Studies030304 developmental biologyBRCA2 ProteinHereditary cancer and cancer-related syndromes [ONCOL 1]associationRetrospective cohort studysnpOdds ratioBRCA1 Protein - geneticsmedicine.diseaseBRCA2 Protein - geneticsMutationOvarian cancerbrca2; snp; brca1; association; ovarian cancer
researchProduct

Genomic profile of breast cancer: costeffectiveness analysis from the Spanish National Healthcare System perspective.

2014

Background: Costeffectiveness analysis of MammaPrint® (70-gene signature) in the diagnosis of early breast cancer as a prognosis assay to study the risk of tumor recurrence to administer adjuvant chemotherapy. Methods: Markov model assuming a cohort of 60-year-old women with breast cancer. Treatment costs and effects were assessed by comparing the 5-year, 10-year and lifetime risk of recurrence using Adjuvant! Online® (online algorithm), 70-gene signature or Oncotype DX® (21-gene assay). Results: 70-gene signature showed a life expectancy of 23.55 years at lifetime. Life expectancy was lower for 21-gene assay and online algorithm, with associated quality-adjusted life year gains up to 0.23 …

Oncologymedicine.medical_specialtyCost effectivenessCost effectivenessCàncer de mamaBreast cancerBreast cancerMammaPrintInternal medicinemedicinePharmacology (medical)Online algorithmEspanyaGynecologyPublic healthmedicine.diagnostic_testbusiness.industryHealth PolicyEconomic analysisGeneral MedicineCost-effectiveness analysisGenomicsAnàlisi cost-beneficimedicine.diseaseSalut públicaGenòmicaSpainCohortLife expectancyAnàlisi econòmicabusinessOncotype DX
researchProduct

Evaluación del grado de conversión de los receptores HER2, RE y RPg entre el cáncer de mama primario y sus respectivas metástasis

2017

Introducción: Tradicionalmente, las decisiones terapéuticas tanto del cáncer de mama precoz como de los estadios avanzados se han basado en los marcadores predictivos del tumor primario, tales como el receptor de estrógeno (RE), el receptor de progesterona (RPg) y el receptor 2 del factor de crecimiento epidérmico humano (HER2), asumiendo que éstos permanecían inmutables a nivel de la recaída metastásica. Objetivos: El objetivo general de esta tesis era investigar si el estado de los receptores HER2, RE y RPg realmente puede cambiar durante la progresión del cáncer de mama y profundizar en las causas y en el impacto clínico de dichos cambios. El objetivo principal era determinar la tasa de …

Oncología Médica320713Receptor de progesterona (RP)MetástasisConversión:CIENCIAS DE LA VIDA [UNESCO]Cáncer de mamaReceptoresHER2UNESCO::CIENCIAS DE LA VIDADiscordanciaReceptor estrogénico (RE)320101
researchProduct